MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.31 1.55

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.28

Max

1.32

Põhinäitajad
By Trading Economics
Sissetulek	2.7M -24M
Aktsiakasum	-0.354
Töötajad	49
EBITDA	-5.3M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+105.38% upside

Turustatistika
By TradingEconomics
Turukapital	-5K 81M
Eelmine avamishind	-0.24
Eelmine sulgemishind	1.31

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2026, 23:36 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. apr 2026, 23:24 UTC

Kuumad aktsiad

Stocks to Watch: Gloo, Broadcom, GitLab

14. apr 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. apr 2026, 21:32 UTC

Suurimad hinnamuutused turgudel

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. apr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. apr 2026, 22:54 UTC

Tulu

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. apr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. apr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. apr 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

14. apr 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 20:32 UTC

Kuumad aktsiad

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. apr 2026, 19:59 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. apr 2026, 19:21 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. apr 2026, 19:09 UTC

Omandamised, ülevõtmised, äriostud

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. apr 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. apr 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

105.38% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 105.38%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.